Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide as Add-on to Dose-reduced Insulin Glargine vs Titrated Insulin Glargine in Type 2 Diabetes and Overweight
NCT05514535Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2022
- Primary completion
- Mar 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 12
01
Overview
A Phase 3 trial of semaglutide in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started Aug 2022; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05514535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05514535.